Fengshan Wang
Overview
Explore the profile of Fengshan Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
1530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liao J, Zhao L, Chen H, Zhao C, Chen S, Guo X, et al.
Mol Pharm
. 2025 Jan;
22(2):708-720.
PMID: 39807649
Numerous diseases, such as diabetic retinopathy and age-related macular degeneration, can lead to retinal neovascularization, which can seriously impair the visual function and potentially result in blindness. The presence of...
2.
Liu C, Xu W, Song X, Tian W, Liu F, Wang F
ACS Omega
. 2025 Jan;
9(52):51062-51072.
PMID: 39758671
The integration of different therapies to enhance the efficacy and minimize adverse reactions has become popular recently. This approach leverages the complementary mechanisms of action of different treatments, which can...
3.
Chen Y, Li Z, Jiang H, Wang L, Zhang Y, Zhang X, et al.
Int J Biol Macromol
. 2024 Oct;
281(Pt 1):136208.
PMID: 39362439
Objectives: Recently, more and more evidences suggest that β-glucans can induce trained immunity and non-specific protections against pathogens. However, most of the reports evaluated the immunological activities of β-glucans through...
4.
Jia W, Li R, Zou F, Li M, Weng H, Shen Q, et al.
Adv Healthc Mater
. 2024 Sep;
13(31):e2402158.
PMID: 39221507
The major drawback of conventional chemotherapeutic treatment is the non-specificity or inability to ascertain and target cancerous cells directly. In this study, an active targeting strategy that is poised to...
5.
Tang W, Hou H, Wang H, Gao X, Zhao F, Di Y, et al.
ACS Appl Mater Interfaces
. 2024 Aug;
16(34):44409-44427.
PMID: 39162197
Cancer presents a significant health threat, necessitating the development of more precise, efficient, and less damaging treatment approaches. To address this challenge, we employed the 1-ethyl-(3-dimethyl aminopropyl) carbodiimide/-hydroxy succinimide (EDC/NHS)...
6.
Chen Y, Wang Y, Li Z, Jiang H, Pan W, Liu M, et al.
Int J Biol Macromol
. 2024 Jul;
276(Pt 1):133733.
PMID: 39002905
Chitosan and its derivatives are ideal nasal vaccine adjuvant to deliver antigens to immune cells. Previously, we successfully used a chitosan derivative, O-(2-Hydroxyl) propyl-3-trimethyl ammonium chitosan chloride (O-HTCC), and a...
7.
Hou H, Li Y, Tang W, Gao D, Liu Z, Zhao F, et al.
Int J Biol Macromol
. 2024 May;
271(Pt 1):132520.
PMID: 38772463
Blocking the tumor nutrient supply through angiogenic inhibitors is an effective treatment approach for malignant tumors. However, using angiogenic inhibitors alone may not be enough to achieve a significant tumor...
8.
Jiang H, Zhang S, Chen Y, Wang F, Jiang W
Int J Biol Macromol
. 2024 Apr;
266(Pt 2):131289.
PMID: 38570002
Intranasal vaccination offers crucial protection against influenza virus pandemics. However, antigens, especially subunit antigens, often fail to induce effective immune responses without the help of immune adjuvants. Our research has...
9.
Li Y, Hou H, Liu Z, Tang W, Wang J, Lu L, et al.
Carbohydr Polym
. 2023 Sep;
320:121255.
PMID: 37659829
Neovascularization is crucial to the occurrence and progression of tumors, and the development of antiangiogenic drugs has essential theoretical value and clinical significance. However, antiangiogenesis therapy alone cannot meet the...
10.
Lu L, Wang L, Zhao L, Liao J, Zhao C, Xu X, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240099
The high vascularization of glioma highlights the potential value of anti-angiogenic therapeutics for glioma treatment. Previously, we designed a novel vascular-targeting and blood-brain barrier (BBB)-penetrating peptide, TAT-AT7, by attaching the...